This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy
by Zacks Equity Research
Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.
Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates
by Kinjel Shah
Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.
Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?
by Zacks Equity Research
Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
J&J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvayli
by Zacks Equity Research
J&J (JNJ) gets approval for Tecvayli (teclistamab) for the treatment of relapsed and refractory multiple myeloma. This marks the first approval for Tecvayli in any country.
AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs
by Zacks Equity Research
The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.
Phibro (PAHC) Q4 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Phibro (PAHC) posts better-than-expected revenues for the fiscal fourth quarter, with robust growth across all segments.
Merck (MRK) Gets FDA Fast Track Tag for Anticoagulant Therapy
by Zacks Equity Research
A phase II study is ongoing on Merck's (MRK) MK-2060 in people with end-stage renal disease receiving hemodialysis.
Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic (MDT) posts better-than-expected results for the fiscal first quarter and maintains earnings and sales outlook for the full year.
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
by Kinjel Shah
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
What's in the Cards for Medtronic (MDT) in Q1 Earnings?
by Zacks Equity Research
Going by the industry-wide macro trend, we expect Medtronic (MDT) to once again report an adverse effect related to the global supply chain issues in fiscal Q1.
Zacks Market Edge Highlights: Merck, PepsiCo, Honeywell, Microsoft and PNC Financial
by Zacks Equity Research
Merck, PepsiCo, Honeywell, Microsoft and PNC Financial have been highlighted in this Market Edge article.
The Story of the Greatest Mom and Pop Investor Ever
by Tracey Ryniec
Anne Scheiber grew $5,000 into $22 million over 50 years. How'd she do it?
Merck (MRK) Enters Into Circular RNA Collaboration With Orna
by Zacks Equity Research
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids
by Zacks Equity Research
With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.
Here's Why You Should Retain Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected results and robust international performance.
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DJD
Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View
by Zacks Equity Research
Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth
by Zacks Equity Research
bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.
National Vision (EYE) Q2 Earnings Top Mark, Revenue View Cut
by Zacks Equity Research
National Vision (EYE) is simultaneously facing demand headwinds across its network of stores, given the current macro environment, as well as supply challenges.